EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025
EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025
Oslo, Norway, 12 August 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce that clinical data from its ACTIVATE Phase 1 trial in patients with liver metastases of colorectal origin (NCT04021277) will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place 17-21 October, 2025 in Berlin, Germany.
Details of the poster presentation are as follows:
Poster #: 4176
Title: First-in-Human Study of Acoustic Cluster Therapy consisting of PS101 combined with Chemotherapy and insonation in Patients with Liver Metastases of Colorectal Cancer Origin
The e-poster will be available on the Company’s website on 18 October, 2025.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: [email protected]